Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC
David Pfister, Natalia Fernández Núñez, Anindita Sinha, Assaf Weiner, Aleksandra Deczkowska, Matthias Pinter, Olivier Govaere, Felicitas Müller, Quentin M. Anstee, T Entgleitner, Roland Rad, Roser Pinyol, Sara Torrecilla, Michael Dudek, Percy A. Knolle, Amy Weber, D Lengenhagger, Josep M. Llovet, Ido Amit, Felix Meissner, Burkhard Becher, Mathias Heikenwälder (2020). Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC. Zeitschrift für Gastroenterologie, 58(03), pp. e71-e71, DOI: 10.1055/a-1143-8420.
Article349 days agoAdverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC
D Pfister, Nicole N Nunez, A Sinha, Assaf Weiner, A Deckowska, Matthias Pinter, Olivier Govaere, F Müller, Quentin M. Anstee, T Entgleitner, Roland Rad, Roser Pinyol, Sara Torrecilla, M Dudek, P Knolle, Angelika Weber, D Lengenhagger, Josep M. Llovet, Ido Amit, F Meissner, B Becher, M Heikenwälder (2020). Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC. Zeitschrift für Gastroenterologie, DOI: 10.1055/s-0039-3402254.
Article349 days agoRamucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)
Matthias Pinter, Masatoshi Kudo, RS Finn, M Morimot, K.-M. Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Howard J. Lim, Khoon Lin Ling, Kazuko Yamaguchi‐Shinozaki, Reigetsu Yoshikawa, C Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu (2020). Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2). Zeitschrift für Gastroenterologie, DOI: 10.1055/s-0040-1712319.
Article349 days agoLBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC
Marta Piqué‐Gili, Anna Vila-Escoda, Marta Casado-Peláez, Roser Pinyol, Ana Hernández de Sande, Verónica Dávalos, Albert Gris‐Oliver, Carla Montironi, Judit Peix, Eduard Porta‐Pardo, Daniela Grases, Sarah Cappuyns, Ezequiel Mauro, Guillem Cano-Segarra, Igor Figueiredo, Giorgio Ioannou, Edgar Gonzalez‐Kozlova, Tim Meyer, Anja Lachenmayer, Jens U. Marquardt, Helen L. Reeves, Julien Edeline, Fabian Finkelmeier, Jörg Trojan, Jean–Frédéric Blanc, Richard Hubner, Matthias Pinter, Tom Luedde, Arndt Vogel, Sacha Gnjatic, Daniela Sia, Vincenzo Mazzaferro, Jeroen Dekervel, Manel Esteller, Josep M. Llovet (2025). LBP-029-YI Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC. , 82, DOI: https://doi.org/10.1016/s0168-8278(25)00447-7.
Article280 days agoBaseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, Tomi Jun, Thomas U. Marron, Anwaar Saeed, Yi‐Hsiang Huang, Mahvish Muzaffar, Matthias Pinter, Lorenz Balcar, Claudia Angela Maria Fulgenzi, Suneetha Amara, Arndt Weinmann, Nicola Personeni, Bernhard Scheiner, Tiziana Pressiani, Musharraf Navaid, Bertram Bengsch, Sonal Paul, Uqba Khan, Dominik Bettinger, Naoshi Nishida, Yehia I. Mohamed, Arndt Vogel, Anuhya Gampa, James Korolewicz, Antonella Cammarota, Ahmed O. Kaseb, Peter R. Galle, Anjana Pillai, Yinghong Wang, Alessio Cortellini, Masatoshi Kudo, Antonio D’Alessio, Lorenza Rimassa, David J. Pinato, Celina Ang (2023). Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. , 15(11), DOI: https://doi.org/10.4251/wjgo.v15.i11.1900.
Article11 days ago